Physician profile
Scott E Dean
NPI 1629074919
$97,152.15
in general payments reported to CMS, 2019-2025
34 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,471 · 2020: $362 · 2021: $1,633 · 2022: $24K · 2023: $20K · 2024: $30K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $4,869 · Food and Beverage: $4,841 · Education: $85.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $37,012.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,400.00 |
| Travel and Lodging | $4,869.02 |
| Food and Beverage | $4,841.03 |
| Education | $85.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $43,904.78 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $42,036.47 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $7,090.41 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $477.85 | 2019-2025 | Jynarque, Voyxact |
| Opko Pharmaceuticals, LLC | $443.59 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $382.74 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $292.49 | 2022-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $272.82 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $246.88 | 2024-2025 | Purified Cortrophin Gel |
| Amgen INC. | $233.69 | 2019-2024 | Krystexxa, Tavneos |
| Baxter Healthcare | $224.30 | 2019-2023 | Renal - Pd |
| Akebia Therapeutics INC | $187.69 | 2019-2024 | Vafseo |
| Novo Nordisk INC | $160.04 | 2019-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $155.44 | 2019-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $132.65 | 2023-2025 | Verquvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $116.76 | 2025 | |
| Glaxosmithkline, LLC. | $106.06 | 2021-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $100.64 | 2020-2024 | Acthar |
| Vantive US Healthcare LLC | $77.95 | 2025 | Renal - Pd |
| Janssen Pharmaceuticals, INC | $73.76 | 2023 | Xarelto |
| Scpharmaceuticals INC. | $63.69 | 2025 | |
| Alnylam Pharmaceuticals INC. | $58.60 | 2022 | |
| Mallinckrodt Enterprises LLC | $53.07 | 2019 | |
| Apellis Pharmaceuticals, INC. | $52.43 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.71 | 2023-2024 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.47 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $24.10 | 2019 | |
| Aurinia Pharma U.S., INC. | $23.25 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.33 | 2022 | |
| Lilly USA, LLC | $19.81 | 2023 | Jardiance |
| Kyowa Kirin, INC. | $15.02 | 2023 | Crysvita |
| Bard Peripheral Vascular, INC. | $13.51 | 2024 | |
| Allergan, INC. | $12.06 | 2019 | |
| Shire North American Group INC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.